The main purpose of this legislation, known as the "Skinny Labels, Big Savings Act," is to create a legal protection, or "safe harbor," for certain actions related to the approval and marketing of generic drugs and biological products. This aims to encourage competition in the pharmaceutical market by allowing generic manufacturers to promote their products without the risk of infringing on existing patents that cover specific methods of use for those drugs.